Annual report [Section 13 and 15(d), not S-K Item 405]

OPERATING SEGMENT (Tables)

v3.25.0.1
OPERATING SEGMENT (Tables)
12 Months Ended
Dec. 31, 2024
OPERATING SEGMENT  
Schedule of financial data for the one reportable segment

    

Year Ended December 31,

    

2024

    

2023

Research and development:

 

  

 

  

Phase 2 study in WM

$

7,422,000

$

12,652,000

Phase 1 study in pediatric tumors

 

3,040,000

 

2,480,000

Manufacturing and related costs

 

10,582,000

 

9,341,000

Pre-clinical projects costs

 

228,000

 

483,000

General research and development costs

 

4,864,000

 

2,310,000

General and administrative

 

25,641,000

 

11,694,000

Other segment items

 

(7,196,000)

 

3,811,000

Segment and consolidated net loss

$

44,581,000

$

42,771,000